Let’s list the good news that emerged Tuesday night from Gilead Sciences’ (GILD) first-quarter earnings report: Sales of the personalized cellular cancer therapy Yescarta totaled $40 million, nicely above the $18 million consensus forecast.
And that’s it.
Disappointing earnings and revenue results. Today, the stock is down 8%. Poor Hep C sales were already in the forecast and Biktarvy, Gilead’s next blockbuster drug, is just gaining approval. https://news.alphastreet.com/gilead-sciences-stock-drops-after-q1-results-miss-consensus/
Comments are closed.